At Cigna Healthcare, 2026 will be a year defined by making healthcare simpler, more affordable and more intuitive for the ...

Wayritz (rilzabrutinib) and Myqorzo (aficamten) were on the list of drugs that were expected to be approved by the FDA in the second half of 2025. The drug regulator approved a total of 46 new drugs ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...

Higher Air Pollution and Extreme Weather Linked to Adult Atopic Dermatitis Climate change and air pollution are growing ...

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight. If approved, ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Researchers reveal ELI-002 2P cancer vaccine shows promise in boosting immune responses for colorectal and pancreatic cancer ...

Self-collected samples to test for cervical cancer are a step in the right direction when it comes to addressing healthcare ...

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...